There are many studies in literature about the topical PUVA
in the treatment of palmoplantar psoriasis, but the results were not consistent.
En Medellin se realizo un estudio a cinco anos con 40 pacientes en estadio IA o IB, quienes recibieron como minimo 58 sesiones de PUVA
y a los cuales, despues de remision clinica e histologica, se les hizo seguimiento.
Olgulara uygulanan tedaviler Erkek Kadin Toplam Tedavi Topikal kortikosteroid 10 (%9,1) 17 (%15,4) 27 (%24,5) Antralin 21 (%19,01) 13 (%11,8) 34 (%30,9) Minoksidil 1 (%0,9) -- 1 (%0,9) Kalsipotriol 1 (%0,9) -- 1 (%0,9) Topikal kalsinorin 1 (%0,9) 1 (%0,9) 2(%1,8) inhibitorleri intralezyonel steroid 4 (%3,6) 7 (%6,3) 11 (%10) Sistemik kortikosteroid 8 (%7,2) 7 (%6,3) 15 (%13,6) PUVA
1 (%0,9) 1 (%0,9) 2 (%1,8) Kombinasyon 9(%8,1) 7 (%6,3) 16(%14,5)
In 2005, Bari et al evaluated the efficacy of UVB and PUVA
therapy in moderate plaque psoriasis10.
(psoralen and UVA) treatment involves taking a drug which increases skin's sensitivity to UV light.
The safety of TL-01 lamp (NB-UVB) with higher therapeutic advantage over broad band UVB and less carcinogenic potential than PUVA
led to continuously increasing use of narrowband UVB 8 (NB-UVB) phototherapy in psoriasis.
treatment in lichen planus: comparison of oral and external methoxsalen regimens.
Bir gallsmada 17 olgunun sonuglan sunulmuc, tek basina PUVA
tedavisi veya PUVA
'nin oral prednisolonia veya potent topikal kortikosteroidlerle kombinasyonu basanli bulunmustur.
also reported a similar response rate of 54% in 13 patients with early-stage CTCL (IB=5, IIA=8) treated with ECP and various forms of adjuvant therapy including: PUVA
, methotrexate, corticosteroids, electron beam radiation, and retinoids (22).
The observed photoprotective activities of oral or topical PL reveal a new avenue in examining the potentially useful field of systemic photoprotection and suggests that PL can be used as adjunct treatment and can make photochemotherapy and phototherapy possibly safe and effective when the control of cutaneous phototoxicity to PUVA
or UVB is a limiting factor in such phototherapies.
was delivered three times weekly starting at a dose of 0.
In addition, carcinogenic risk is associated with oral psoralen + UVA photochemotherapy (PUVA
) and is probable for local PUVA